June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

Of the 289 patients in the study, 39 (13.5 %) were treatment-naïve. Table 1 summarizes key baseline characteristics of the treatment-naïve patients and study eyes. Eighteen patients were diagnosed ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

Please provide your email address to receive an email when new articles are posted on . According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual ...

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin. Patients who have diabetic macular edema ...

At the American Academy of Ophthalmology (AAO) annual meeting, new data were presented from a 7-month analysis on OTX-TKI, an axitinib (Inlyta) intravitreal implant being evaluated for the treatment ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BARCELONA, Spain — A subgroup analysis of the DAVIO 2 ...

Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...

brolucizumab-dbll Beovu 6mg/0.05mL soln for intravitreal inj 6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks. ranibizumab Lucentis 6mg/mL ...

Ocular Therapeutix (NASDAQ:OCUL) reported 10-month interim data from a U.S. phase 1 trial of OTX-TKI, an intravitreal hydrogel implant containing axitinib. Axitinib is a tyrosine kinase inhibitor ...

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...